← Compound index
COMPOUND RECORD / SIGUMIR

SigumirСигумир

A peptide mixture extracted from calf or pig cartilage, described in Russian joint-disease reports.

Source linked

What the studies found

Comparison in people · 2006

Sigumir: clinical report on a tissue-derived preparation

The 2005–2006 report describes symptom changes over 30–45 days, without substantial radiographic improvement. The English brochure repeats its cohort and percentages under Cartalax; preparation attribution and cohort independence are unresolved.

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Study notes · methods, sources and limitations

Participants or model 64 patients: 33 adjunctive Sigumir; 31 controls. Knee osteoarthritis, spinal degeneration or osteoporosis.

Important limitations

  • Reported symptom percentages are difficult to reconcile with the small diagnostic subgroups. Allocation and blinding are unclear. Symptom relief does not establish cartilage regeneration. Commercially reproduced institute report; independent peer review and independent replication are not established by this document. Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date · Institute report — commercial reproduction

Original source or citation ↗

Study results and tables ↗

Comparison in people · 2012

Application of bioregulating therapy in complex treatment of temporomandibular joint diseases in people of elderly and senile age

Pain, mouth opening and chewing
Improvement reportedNo numerical outcome changes or comparison-group counts supplied

The indexed abstract describes adjunctive Sigumir in older patients with temporomandibular joint disease. Full clinical appraisal remains pending.

Study notes · methods, sources and limitations

Participants or model 62 older patients with temporomandibular joint diseases

Design 62 older patients with temporomandibular-joint disease; Sigumir as part of prosthetic, functional and pharmacological care.

Important limitations

  • The abstract does not establish allocation, blinding, arm sizes or an effect estimate. Full methods remain to be acquired. This is a distinct joint-disease report, not replication of every claim in the earlier institute report.
  • Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Adv Gerontol. 2012;25(1):181–186. PMID 22708467 · Journal publication

Original source or citation ↗

Study results and tables ↗
01 / OVERVIEW

About Sigumir

Identity / background source ↗

Research background

Sigumir is a cartilage-associated peptide preparation studied for joint symptoms. The brochure repeats its outcome table under Cartalax, leaving product attribution uncertain.

Compound class
Tissue-derived peptide preparation
Research collection
Peptide bioregulation · editorial grouping
Institutions in linked studies
Medical Center, St. Petersburg Institute of Bioregulation and Gerontology
Source review
Review dates and the material assessed are listed with each publication below.
02 / HOW TO READ THE RESEARCH

Understanding the evidence

Human research

64 patients: 33 adjunctive Sigumir; 31 controls. Knee osteoarthritis, spinal degeneration or osteoporosis.

Study methods

Small comparative institute report; allocation, blinding and outcome interpretation require caution

Independent replication

Independent replication not established in this collection

Source access

Report reproduction linked; source language and review scope shown per record

Safety evidence

Short-term reports do not establish long-term safety or equivalence to current products

Open a topic for the evidence assessment.

More findings, background and history

What remains unclear

The original report and protocol would clarify group sizes, background treatment and translation. Independent replication and equivalence to current products remain uncertain.

Human reports are linked; their presence does not establish effectiveness. Several publications can describe the same participants.

Browse original study records ↗

Explore the expanded peptide research collection and unresolved source trails ↗

View this preparation in the Khavinson evidence map ↗

03 / SOURCE RECORDS

Findings by study

Tissue-preparation reports: comparisons, source limits and remaining gaps ↗

Explore related research ↗

Comparison in people · 2006

Sigumir: clinical report on a tissue-derived preparation

The 2005–2006 report describes symptom changes over 30–45 days, without substantial radiographic improvement. The English brochure repeats its cohort and percentages under Cartalax; preparation attribution and cohort independence are unresolved.

Study notes and original source
2006Human comparative studyRussian-language source

Sigumir: clinical report on a tissue-derived preparation

Report attributed to · Medical Center, St. Petersburg Institute of Bioregulation and Gerontology

Tissue-derived mixture / named preparation · Institute report — commercial reproduction

St. Petersburg Institute of Bioregulation and Gerontology Medical Center (report attribution) · Institute clinical report (commercial reproduction); 2006 study/report date, not website publication date

The 2005–2006 report describes symptom changes over 30–45 days, without substantial radiographic improvement. The English brochure repeats its cohort and percentages under Cartalax; preparation attribution and cohort independence are unresolved.

Population / setting
64 patients: 33 adjunctive Sigumir; 31 controls. Knee osteoarthritis, spinal degeneration or osteoporosis.
Source reviewed
Russian report reproduced on a commercial website; population, comparison and reported outcomes checked. Signed original and full protocol not authenticated.
Study limitations
  • Reported symptom percentages are difficult to reconcile with the small diagnostic subgroups. Allocation and blinding are unclear. Symptom relief does not establish cartilage regeneration.
  • Commercially reproduced institute report; independent peer review and independent replication are not established by this document.
  • Short-term reporting without a complete adverse-event protocol cannot establish long-term safety. Preparation equivalence to current products or synthetic peptides is unproven.

Reviewed 2026-10-02.

Read the source ↗

Comparison in people · 2012

Application of bioregulating therapy in complex treatment of temporomandibular joint diseases in people of elderly and senile age

The indexed abstract describes adjunctive Sigumir in older patients with temporomandibular joint disease. Full clinical appraisal remains pending.

Study notes and original source
2012Human comparative studyEnglish abstract

Application of bioregulating therapy in complex treatment of temporomandibular joint diseases in people of elderly and senile age

Named tissue-derived preparation · Journal publication

A. K. Iordanishvili, V. V. Samsonov, L. N. Soldatova, A. A. Polens, G. A. Ryzhak · Adv Gerontol. 2012;25(1):181–186. PMID 22708467

The indexed abstract describes adjunctive Sigumir in older patients with temporomandibular joint disease. Full clinical appraisal remains pending.

Results and tables

Reported findings and study design

62 older patients with temporomandibular-joint disease; Sigumir as part of prosthetic, functional and pharmacological care.

Population or model 62 older patients with temporomandibular joint diseases

Results · Previously retrieved indexed abstract; numerical statements checked against the saved source text
MeasureResultComparison, timing and statistics
Pain, mouth opening and chewingImprovement reportedNo numerical outcome changes or comparison-group counts supplied

Values describe this study and its comparison. Unreported effect sizes and missing denominators have not been inferred.

Source for these results ↗ · Reviewed 2026-10-29

Population / setting
62 older patients with temporomandibular joint diseases
Source reviewed
PubMed citation and abstract checked; full paper not reviewed.
Study limitations
  • The abstract does not establish allocation, blinding, arm sizes or an effect estimate. Full methods remain to be acquired.
  • This is a distinct joint-disease report, not replication of every claim in the earlier institute report.

Reviewed 2026-10-02.

Read the source ↗

Follow shared publications or research classes. These links do not establish equivalent effects between compounds.

Research collection curated by @PepMariner · editorial standards. Send a source correction ↗

Browse bibliography & PDFs ↗